Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Completed
Conditions studied: Melanoma
In brief
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab
Key facts
- Study ID
- NCT07091695
- Run by
- Bristol-Myers Squibb
- People needed
- 100
- Starts
- 2025-05-11
- Expected to finish
- 2025-11-06
- Last updated by the study team
- 2025-11-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants at least 18 years old at diagnosis of clinically palpable stage III resectable melanoma
- Participants treated with nivolumab+relatimab (nivo+rela) or nivolumab+ipilimumab (nivo+ipi) in the neoadjuvant setting
- Participants with at least 6 months of follow-up from initiation of neoadjuvant therapy, unless deceased prior to 6 months of follow-up
You may not qualify if…
- Participants received nivo+rela or nivo+ipi for clinically palpable stage III resectable melanoma as part of a therapeutic clinical trial
- Participants had history of diagnosis of any malignancy (except for non-melanoma skin cancer) in the last 2 years.
- Participants received adjuvant nivo+rela or adjuvant nivo+ipi after neoadjuvant nivo+ipi
- Participants received adjuvant nivo+ipi after neoadjuvant nivo+rela
- Participants received any systemic therapy prior to the initiation of neoadjuvant nivo+rela or nivo+ipi
Where it is running
- Cardinal Health — Dublin, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.